>>With a company as large as BMY, there are always pending clinical developments that could be material to an M&A transaction<< True, BMY is not a small one-trick pony. Could you educate me on how the suitor will make the M&A economics work if pending clinical development candidates fail to fill the plavix gap in 2012, or was that already built in the stock price? Thanks again!
Market Data 
Markets 
AI
